The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Effect of Chronic Intermittent Administration of Inhaled Tobramycin on Respiratory Microbial Flora in Patients with Cystic Fibrosis
Open accessAbstract
Pseudomonas aeruginosa endobronchial infection causes significant morbidity and mortality among cystic fibrosis patients. Microbiology results from two multicenter, double-blind, placebo-controlled trials of inhaled tobramycin in cystic fibrosis were monitored for longitudinal changes in sputum microbial flora, antibiotic susceptibility, and selection of P. aeruginosa isolates with decreased tobramycin susceptibility. Clinical response was examined to determine whether current susceptibility standards are applicable to aerosolized administration. Treatment with inhaled tobramycin did not increase isolation of Burkholderia cepacia, Stenotrophomonas maltophilia, or Alcaligenes xylosoxidans; however, isolation of Candida albicans and Aspergillus species did increase. Although P. aeruginosa tobramycin susceptibility decreased in the tobramycin group compared with that in the placebo group, there was no evidence of selection for the most resistant isolates to become most prevalent. The definition of resistance for parenteral administration does not apply to inhaled tobramycin: too few patients had P. aeruginosa with a tobramycin MIC >/=16 microgram/mL to define a new break point on the basis of clinical response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Cited by 16,875
National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · Pediatrics · doi:10.1542/peds.65.1.187 · Cited by 14,751
Antibiotics in Laboratory Medicine.
(1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-93-4-653_4 · Cited by 2,779
Clinical Microbiology Procedures Handbook
(2016) · ASM Press eBooks · doi:10.1128/9781555818814 · Cited by 2,240
Changes in the normal maximal expiratory flow-volume curve with growth and aging.
Knudson, R. J., Lebowitz, M. D., Holberg, C. J., & Burrows, B. A. (1983) · PubMed · doi:10.1164/arrd.1983.127.6.725 · Cited by 1,907
Intermittent Administration of Inhaled Tobramycin in Patients with Cystic Fibrosis
Ramsey, B. W., Pepe, M. S., Quan, J. M., Otto, K. L., Montgomery, A. B., Williams-Warren, J., Vasiljev-K, M., Borowitz, D., Bowman, C. M., Marshall, B. C., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901073400104 · Cited by 1,300
Self-citationThe changing epidemiology of cystic fibrosis
FitzSimmons, S. C. (1993) · The Journal of Pediatrics · doi:10.1016/s0022-3476(05)83478-x · Cited by 928
Microbiology of airway disease in patients with cystic fibrosis
Gilligan, P. H. (1991) · Clinical Microbiology Reviews · doi:10.1128/cmr.4.1.35 · Cited by 529
Efficacy of Aerosolized Tobramycin in Patients with Cystic Fibrosis
Ramsey, B. W., Dorkin, H. L., Eisenberg, J. D., Gibson, R. L., Harwood, I. R., Kravitz, R. M., Schidlow, D. V., Wilmott, R. W., Astley, S. J., McBurnie, M. A., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199306173282403 · Cited by 458
Self-citationMicrobiology of Sputum from Patients at Cystic Fibrosis Centers in the United States
Burns, J. L., Emerson, J., Stapp, J. R., Yim, D. L., Krzewinski, J., Louden, L., Ramsey, B. W., & Clausen, C. R. (1998) · Clinical Infectious Diseases · doi:10.1086/514631 · Cited by 421
Self-citation
Cited by
Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis
Gibson, R. L., Burns, J. L., & Ramsey, B. W. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200304-505so · Cited by 1,633
Self-citationStenotrophomonas maltophilia: an Emerging Global Opportunistic Pathogen
Brooke, J. S. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.00019-11 · Cited by 1,434
Stevens, D. A., Moss, R. B., Kurup, V. P., Knutsen, A. P., Greenberger, P., Judson, M. A., Denning, D. W., Crameri, R., Brody, A. S., Light, M., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/376525 · Cited by 790
Pseudomonas Aeruginosa Biofilms in Cystic fibrosis
H⊘iby, N., Ciofu, O., & Bjarnsholt, T. (2010) · Future Microbiology · doi:10.2217/fmb.10.125 · Cited by 666
Mulcahy, L. R., Burns, J. L., Lory, S., & Lewis, K. (2010) · Journal of Bacteriology · doi:10.1128/jb.01651-09 · Cited by 631
Self-citationAntibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus
Döring, G., Conway, S. P., Heijerman, H. G. M., Hodson, M. E., Høiby, N., Smyth, A., Touw, D. J., & the Consensus Committee, F. (2000) · European Respiratory Journal · doi:10.1034/j.1399-3003.2000.16d30.x · Cited by 620
Medically important bacterial-fungal interactions
Peleg, A. Y., Hogan, D. A., & Mylonakis, E. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2313 · Cited by 619
Pseudomonas - Candida Interactions: An Ecological Role for Virulence Factors
Hogan, D. A., & Kolter, R. (2002) · Science · doi:10.1126/science.1070784 · Cited by 579
A Pseudomonas aeruginosa quorum‐sensing molecule influences Candida albicans morphology
Hogan, D. A., Vik, Å., & Kolter, R. (2004) · Molecular Microbiology · doi:10.1111/j.1365-2958.2004.04349.x · Cited by 575
A bacterial cell–cell communication signal with cross‐kingdom structural analogues
Wang, L., He, Y., Gao, Y., Wu, J. E., Dong, Y., He, C., Wang, S. X., Weng, L., Xu, J., Tay, L., et al. (2004) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03883.x · Cited by 442
Fauvart, M., De Groote, V. N., & Michiels, J. (2011) · Journal of Medical Microbiology · doi:10.1099/jmm.0.030932-0 · Cited by 425
Farnesol, a common sesquiterpene, inhibits PQS production in Pseudomonas aeruginosa
Cugini, C., Calfee, M. W., Farrow, J. M., Morales, D. K., Pesci, E. C., & Hogan, D. A. (2007) · Molecular Microbiology · doi:10.1111/j.1365-2958.2007.05840.x · Cited by 332
Infection Control in Cystic Fibrosis
Saiman, L., & Siegel, J. (2004) · Clinical Microbiology Reviews · doi:10.1128/cmr.17.1.57-71.2004 · Cited by 324
Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Langton Hewer, S. C., & Smyth, A. R. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004197.pub4 · Cited by 324
Smith, A. L., Fiel, S. B., Mayer-Hamblett, N., Ramsey, B., & Burns, J. L. (2003) · Chest · doi:10.1378/chest.123.5.1495 · Cited by 307
Self-citationSaiman, L. (2003) · American Journal of Infection Control · doi:10.1067/mic.2003.78 · Cited by 307
Pseudomonas aeruginosa lasR mutants are associated with cystic fibrosis lung disease progression
Hoffman, L. R., Kulasekara, H. D., Emerson, J., Houston, L. S., Burns, J. L., Ramsey, B. W., & Miller, S. I. (2009) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2008.09.006 · Cited by 301
Self-citationInhaled Colistin in Patients with Bronchiectasis and Chronic Pseudomonas aeruginosa Infection
Haworth, C. S., Foweraker, J. E., Wilkinson, P., Kenyon, R. F., & Bilton, D. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201312-2208oc · Cited by 264
Lopez-Medina, E., Fan, D., Coughlin, L. A., Ho, E. X., Lamont, I. L., Reimmann, C., Hooper, L. V., & Koh, A. Y. (2015) · PLOS Pathogens · doi:10.1371/journal.ppat.1005129 · Cited by 143
Trejo-Hernández, A., Andrade-Domínguez, A., Hernández, M., & Encarnación, S. (2014) · The ISME Journal · doi:10.1038/ismej.2014.53 · Cited by 135
Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis
Smith, S., Rowbotham, N. J., & Regan, K. H. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001021.pub3 · Cited by 92
Máiz, L., Vendrell, M., Olveira, C., Girón, R., Nieto, R., & Martínez-García, M. Á. (2015) · Respiration · doi:10.1159/000381289 · Cited by 69
Briard, B., Mislin, G. L. A., Latgé, J.-P., & Beauvais, A. (2019) · Journal of Fungi · doi:10.3390/jof5020048 · Cited by 69
Risk factors for persistent Aspergillus respiratory isolation in cystic fibrosis.
Hong, G., Psoter, K. J., Jennings, M. T., Merlo, C. A., Boyle, M. P., Hadjiliadis, D., Kawut, S. M., & Lechtzin, N. (2018) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2018.01.008 · Cited by 59
Metadata
- Authors
- Burns, J. L., Van Dalfsen, J. M., Shawar, R. M., Otto, K. L., Garber, R. L., Quan, J. M., Montgomery, A. B., Albers, G. M., Ramsey, B. W., & Smith, A. L.
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 1999-05
- Volume
- 179
- Issue
- 5
- Pages
- 1190-1196
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2113263701
- Cited by
- 289
- References
- 18
- FWCI
- 10.97
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.